Q3 Results

A combined 60.9 million equity shares representing 36.5 per cent of total equity of NOCIL changed hands on the NSE and BSE till 11:25 AM on Tuesday.

In the December quarter, Shree Ram Twistex posted a net profit of ₹3.7 crore, as compared to ₹2.2 crore year-on-year (Y-o-Y), up 70 per cent.

In the ferrous space, analysts at ICICI Securities don't foresee any major impact due to ongoing geopolitical tensions as exports share of total steel production is pegged at <6 per cent.

Infosys's stock price has corrected 25 per cent thus far in the calendar year 2026, as against 11.4 per cent fall in Nifty 50, on likely threat to revenue growth.

Ipca Labs hit a 52-week high of ₹1,624 on the BSE in Tuesday's intra-day trade amid heavy volumes and was seen inching towards its record high of ₹1,757.55 touched on January 3, 2025.

Analysts believe the recent stock market correction due to the ongoing conflict between Iran and Israel-US and resultant dislocations in stock prices, presents an opportunity to add 'better' stocks.

Till 12:57 PM on Monday, a combined 19.96 million shares representing 1.23 per cent of Bandhan Bank's total equity changed hands on the NSE (19.15 million shares) and BSE (0.81 million shares).

A combined 27.84 million equity shares representing 8.75 per cent of total equity of the Zydus Wellness changed hands on the NSE and BSE till 01:37 PM on Friday.

The average trading volumes on the ATGL counter jumped over 20-fold with a combined 16.44 million equity shares changing hands on the NSE and BSE till 01:16 PM.

Sun Pharma is transitioning its US business from low-margin generics to high-value specialty and innovative therapies.

Thus far in the calendar year 2026, TCS's market price plunged 23 per cent, as against 7.4 per cent decline in Nifty 50, data shows. The NIfty IT index lost over 1 per cent in trade on Tuesday.

In the past four trading days, the stock price of Natco Pharma has surged 10 per cent after the company announced the launch of Pomalidomide Capsules (generic of Pomalyst) in the US market.

Emcure Pharmaceuticals stock was quoting close to its 52-week high of ₹1,585.50 on Monday, and has surged up to 62% in the last one year.

Meesho said the Assessment Order along with the Demand Notice does not have any major adverse impact on the company's financial position, operations, or other activities.

On a quarter-on-quarter (Q-o-Q) basis, the company's net loss widened to ₹178.38 crore, as compared to a loss of ₹100.16 crore in Q2FY26

The management has maintained a double-digit volume growth forecast for Q4FY26 and FY27E, targeting 17-18 per cent EBITDA margin for Plumbing division and 12 -13 per cent for Paints & Adhesives.

Crisil Ratings believes that the Belrise group will maintain its strong position in the auto components industry backed by its established customer relationships and a diversified product portfolio.

Fractal Analytics reported a 10.5% rise in Q3 profit to ₹102.6 crore, with revenue up 21% year-on-year as healthcare, life sciences and BFS demand lifted its first post-listing results

Thus far in the calendar year 2026, BEL has outperformed the market by surging 16%, as compared to 6.6% decline in the BSE Sensex.

Acutaas Chemicals management has revised revenue guidance upwards from 25 per cent to around 30 per cent growth for FY26.